PT886
- Generic Name
- PT886
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
- Associated Conditions
- -
- Associated Therapies
- -
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA
Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy. PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates for these aggressive cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath